Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intersect ENT (XENT), Vericel Corp (VCEL) and Mallinckrodt (MNK).
Intersect ENT (XENT)
In a report released today, Suraj Kalia from Northland Securities assigned a Hold rating to Intersect ENT, with a price target of $28. The company’s shares opened today at $34.11.
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 13.8% and a 59.9% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Strata Skin Sciences Inc, and Obalon Therapeutics Inc.
Intersect ENT has an analyst consensus of Moderate Buy, with a price target consensus of $34.33, representing a 0.6% upside. In a report released today, BTIG also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
Vericel Corp (VCEL)
Oppenheimer analyst Kevin Degeeter maintained a Buy rating on Vericel Corp today and set a price target of $23. The company’s shares opened today at $20.87, close to its 52-week high of $21.01.
Degeeter said:
“On 2/26/19, Vericel reported 4Q18 results that beat consensus and provided 2019 guidance in line with prior consensus. While we expect deceleration of top line growth in 1H19 to result in share price volatility, we also see modest potential upside to 2019 revenue guidance and better than expected operating leverage. We encourage investors to track number of new surgeons trained as a leading indicator of future growth. While we view productivity of newly trained sales reps expected to enter the field April 1 as important to sustaining growth for MACI, we do not expect the investment in commercial infrastructure to translate to incremental revenue until 4Q19 and into 2020. On net, we are revising 2019E revenue from $111.5M to $112.6M (guidance $108-112M) and EPS from ($0.10) to $0.09.”
According to TipRanks.com, Degeeter is a 4-star analyst with an average return of 16.2% and a 53.1% success rate. Degeeter covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences Inc, Molecular Templates Inc, and Neon Therapeutics Inc.
Vericel Corp has an analyst consensus of Moderate Buy, with a price target consensus of $21.50.
Mallinckrodt (MNK)
In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Hold rating on Mallinckrodt, with a price target of $22. The company’s shares opened today at $23.99.
Rivkind Koffler commented:
“We had modeled $821.2M and $2.26 and note that specialty generics sales of $183.8M beat our estimate of $172.3M (ex-Amitiza) and Amitiza and INOmax also outperformed our expectations.”
According to TipRanks.com, Koffler is a 4-star analyst with an average return of 7.7% and a 40.9% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Assertio Therapeutics Inc, and Eagle Pharmaceuticals Inc.
Currently, the analyst consensus on Mallinckrodt is a Moderate Buy with an average price target of $32.29.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
